SPAGO.ST
Spago Nanomedical AB (publ) [SPAGO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SPAGO.ST Stock Summary
Top 10 Correlated Stocks
SPAGO.ST
In the News
SPAGO.ST Financial details
Company Rating
-
Market Cap
65.17M
Income
-38.53M
Revenue
1.2M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
07 Feb 2024
P/E
-0.77
Forward P/E
-
PEG
0.22
P/S
116.76
P/B
0.19
P/C
-
P/FCF
-1.8
Quick Ratio
4.68
Current Ratio
5.25
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.39
EPS next Y
-
EPS next Q
-
EPS this Y
-27.12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-13.73%
Revenue last 5Y
109.23%
Revenue Q/Q
169.74%
EPS Q/Q
6.02%
-
-
-
-
SMA20
-
SMA50
-
SMA100
5%
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-22%
ROC
-0.25%
Gross Margin
-3218%
Oper. Margin
-6726%
Profit Margin
-6582%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.195801-0.859615
52W High
-
52W Low
-
RSI
56.76
Rel Volume
1.2
Avg Volume
128.55K
Volume
154.89K
Perf Week
23.29%
Perf Month
2.74%
Perf Quarter
30.06%
Perf Half Y
20.97%
-
-
-
-
Beta
2.098
-
-
Volatility
0.02%, 0.02%
Prev Close
10.29%
Price
0.225
Change
-5.46%
Company Profile
- Volume Average 128.55K
- Market Capitalization 65.17M
- Employee 13
- CEO Dr. Mats Hansen M.Sc., Ph.D.
- Headquarters Lund,SE
- IPO Date 2013-01-16
-
Website
https://spagonanomedical.se 
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
